GSK pushes more data for shingles vaccine, but no filing yet

GlaxoSmithKline's shingles vaccine continues to demonstrate strong efficacy in all ages in Phase III trials but the company doesn't plan to file the product just yet.

GlaxoSmithKline's shingles vaccine continues to demonstrate strong efficacy in all ages in Phase III trials but the company doesn't plan to file the product just yet.

Late-stage data for GSK's investigational vaccine candidate for the prevention of shingles, HZ/su (GSK1437173A), were presented at the European Society...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category